Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oligonucleotide
Therapeutic Area : Technology
Study Phase : Undisclosed
Recipient : Luxna Biotech
Deal Size : Undisclosed
Deal Type : Financing
Details : Luxna Biotech will use this capital to drive collaboration with pharmaceutical companies and academia by strengthening its platform technologies for oligonucleotide therapeutics.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : Undisclosed
February 10, 2020
Lead Product(s) : Oligonucleotide
Therapeutic Area : Technology
Highest Development Status : Undisclosed
Recipient : Luxna Biotech
Deal Size : Undisclosed
Deal Type : Financing
LOOKING FOR A SUPPLIER?
Reset All
